Depressive Disorder, Major Clinical Trial
— E-COMPARED_CHOfficial title:
European Comparative Effectiveness Research on Internet-based Depression Treatment - Swiss Trial
Verified date | September 2017 |
Source | University of Bern |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To compare the clinical and cost-effectiveness of blended Cognitive Behavioural Therapy (CBT) for adults with major depressive disorder (MDD) with treatment as usual (TAU) in Swiss patients in secondary care
Status | Completed |
Enrollment | 50 |
Est. completion date | July 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Being 18 years of age or older - Meet DSM-IV diagnostic criteria for MDD confirmed by MINI International Neuropsychiatric Interview version 5.0 - Informed Consent - Having access to a PC and Internet connection - Having a Smartphone that is compatible with the mobile component of the intervention - Understanding of the German language spoken and written Exclusion Criteria - Current high risk for suicide according to the MINI Interview section C - Serious psychiatric co-morbidity: substance dependence, bipolar affective disorder, psychotic illness, obsessive compulsive disorder, as established at the MINI interview - Currently receiving psychological treatment for depression - Being unable to comprehend the spoken and written language (German) - Not having access to a PC and fast Internet connection (i.e. broadband or comparable). - Not having a Smartphone that is compatible with the mobile component of the intervention that is offered or not willing to carry a Smartphone during the duration of treatment |
Country | Name | City | State |
---|---|---|---|
Switzerland | Department of Clinical Psychology and Psychotherapy | Bern | |
Switzerland | Sanatorium Kilchberg | Kilchberg | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Bern |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient Health Questionnaire-9 (PHQ-9) | 18 weeks | ||
Secondary | Assessment of Quality of Life (AQoL-6D) | Baseline, 12 weeks, 18 weeks, 6 months, and 12 months | ||
Secondary | Quick Inventory of Depressive Symptomatology Self-Report (QIDS-16-SR) | Baseline, 12 weeks, 18 weeks, 6 months, and 12 months | ||
Secondary | MINI International Neuropsychiatric Interview (M.I.N.I; Ackenheil et al., 1999) | Baseline, 18 weeks, and 12 months | ||
Secondary | EuroQoL (EQ-5D-5L; Herdman et al., 2011) | Baseline, 12 weeks, 18 weeks, 6 months, and 12 months | ||
Secondary | Questionnaires on Costs Associated with Psychiatric Illness (TiC-P; Hakkaart-van Rooijen, van Straten, Donker, Tiemens, 2002) | Baseline, 12 weeks, 18 weeks, 6 months, and 12 months | ||
Secondary | Client Satisfaction Questionnaire (CSQ-8; Nguyen, Attkinson, & Stegner, 1983) | 12 weeks, and 18 weeks | ||
Secondary | System Usability Scale (SUS; Brooke, 1996) | 12 weeks, and 18 weeks | ||
Secondary | Patient Health Questionnaire-9 (PHQ-9) | Baseline, 12 weeks, 6 months, and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05415397 -
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
|
Phase 3 | |
Recruiting |
NCT05988333 -
Psychoeducational Intervention for Families With a Member Affected by Major Depression
|
N/A | |
Completed |
NCT02919501 -
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
|
Phase 2 | |
Completed |
NCT00976560 -
Clinical Study to Test a New Drug to Treat Major Depression
|
Phase 2 | |
Recruiting |
NCT05518149 -
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Not yet recruiting |
NCT06303076 -
Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial
|
Phase 4 | |
Not yet recruiting |
NCT05901571 -
Acupuncture and Escitalopram for Treating Major Depression Clinical Study
|
N/A | |
Suspended |
NCT02546024 -
Predictors of Treatment Response in Late-onset Major Depressive Disorder
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01583400 -
Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial
|
N/A | |
Completed |
NCT01152996 -
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
|
Phase 3 | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00366652 -
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
|
Phase 3 | |
Completed |
NCT00384033 -
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT00369343 -
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00149643 -
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 |